Special Issue "Signaling Pathway in Gastrointestinal Cancer"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 30 April 2022.

Special Issue Editor

Prof. Dr. Tianhui Hu
E-Mail Website
Guest Editor
Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, China
Interests: colorectal cancers; tumor metastasis;tumor microenvironment

Special Issue Information

Dear Colleagues,

Gastrointestinal (GI) cancers are among the most common cancers with high morbidity and mortality worldwide. In addition to traditional chemotherapy, targeted therapy and immunotherapy further improve the therapeutic efficacy and survival rate of GI cancer patients. Better understanding of the signal pathways involved in GI cancers will surely help in developing new drugs and treatment methods and improving patients’ survival. In this Special Issue, we want to present the most recent proceedings of the signal pathways involved in the development and metastasis of GI cancers. The main focus of the issue is the basic-translational oncology of GI cancer. Topics of interests include, but are not limited to, signal pathways related to tumor development, metastasis, microenvironment, immunology and immunotherapy, targeted and next-generation therapeutics, chemotherapy and radiotherapy, and drug resistance.

This Special Issue will highlight the current state of the art in the signal pathways in GI cancers, and will cover both basic and translational aspects that advance our understanding of signal pathways in GI cancer.

Dr. Tianhui Hu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancer
  • Wnt signaling
  • EGFR signaling
  • metastasis
  • tumor microenvironment
  • immunotherapy
  • targeted therapy
  • drug resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer
Cancers 2022, 14(2), 383; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020383 - 13 Jan 2022
Viewed by 109
Abstract
Abnormal angiogenesis is one of the important hallmarks of colorectal cancer as well as other solid tumors. Optimally, anti-angiogenesis therapy could restrain malignant angiogenesis to control tumor expansion. PELP1 is as a scaffolding oncogenic protein in a variety of cancer types, but its [...] Read more.
Abnormal angiogenesis is one of the important hallmarks of colorectal cancer as well as other solid tumors. Optimally, anti-angiogenesis therapy could restrain malignant angiogenesis to control tumor expansion. PELP1 is as a scaffolding oncogenic protein in a variety of cancer types, but its involvement in angiogenesis is unknown. In this study, PELP1 was found to be abnormally upregulated and highly coincidental with increased MVD in CRC. Further, treatment with conditioned medium (CM) from PELP1 knockdown CRC cells remarkably arrested the function of human umbilical vein endothelial cells (HUVECs) compared to those treated with CM from wildtype cells. Mechanistically, the STAT3/VEGFA axis was found to mediate PELP1-induced angiogenetic phenotypes of HUVECs. Moreover, suppression of PELP1 reduced tumor growth and angiogenesis in vivo accompanied by inactivation of STAT3/VEGFA pathway. Notably, in vivo, PELP1 suppression could enhance the efficacy of chemotherapy, which is caused by the normalization of vessels. Collectively, our findings provide a preclinical proof of concept that targeting PELP1 to decrease STAT3/VEGFA-mediated angiogenesis and improve responses to chemotherapy due to normalization of vessels. Given the newly defined contribution to angiogenesis of PELP1, targeting PELP1 may be a potentially ideal therapeutic strategy for CRC as well as other solid tumors. Full article
(This article belongs to the Special Issue Signaling Pathway in Gastrointestinal Cancer)
Show Figures

Figure 1

Back to TopTop